Scientific reports
June 4, 2025
Inge Hahne, Julia Segerer, Marco Zierhut et al.
3 citations
Mindfulness is linked to fewer positive and depressive symptoms in people with schizophrenia spectrum disorders, and psychological flexibility appears to partly explain how mindfulness relates to negative and depressive symptoms. In a cross-sectional study of 94 adults with these disorders, higher mindfulness scores correlated with lower positive and depressive symptom severity and with greater psychological flexibility. Statistical mediation analyses showed that psychological flexibility significantly mediated the relationship between mindfulness and both negative and depressive symptoms. The findings suggest psychological flexibility may be a mechanism through which mindfulness-based interventions reduce certain symptoms, though longitudinal research is needed to confirm this.
Schizophrenia bulletin
November 16, 2024
Inge Hahne, Marco Zierhut, Niklas Bergmann et al.
3 citations
A yoga-based group intervention (YoGI) added to treatment-as-usual is feasible and acceptable for inpatients with schizophrenia spectrum disorders (SSD). In a randomized controlled trial with 50 inpatients, YoGI plus treatment-as-usual showed 95% protocol adherence, 91-94% retention, and a 6% dropout rate. Compared to treatment-as-usual alone, the yoga group had significant improvements in positive symptoms, depression, cognitive fusion, and a mindfulness subscale. Medium-to-large improvements were also seen in body mindfulness, negative and general symptoms, anxiety, stress, quality of life, and attention. No severe adverse events occurred. The findings suggest YoGI may provide benefits beyond standard care, but further robust trials are needed.
medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Combining intranasal oxytocin with mindfulness-based group therapy may improve negative symptoms in schizophrenia spectrum disorders. In a pilot study, 47 participants received either oxytocin or placebo before four therapy sessions. Only the oxytocin group showed significant reductions in negative symptoms from baseline to post-intervention and at a 4-week follow-up, with small between-group effects favoring oxytocin at follow-up. No serious adverse events occurred. The findings support further large-scale trials.